Show simple item record

dc.contributor.authorCramer, Elisabeth P.en_US
dc.contributor.authorGlenthøj, Andreasen_US
dc.contributor.authorHäger, Mattiasen_US
dc.contributor.authorJuncker-Jensen, Annaen_US
dc.contributor.authorEngelholm, Lars H.en_US
dc.contributor.authorSantoni-Rugiu, Ericen_US
dc.contributor.authorLund, Leif R.en_US
dc.contributor.authorLaerum, Ole D.en_US
dc.contributor.authorCowland, Jack B.en_US
dc.contributor.authorBorregaard, Nielsen_US
dc.date.accessioned2013-04-08T13:13:11Z
dc.date.available2013-04-08T13:13:11Z
dc.date.issued2012-06-21eng
dc.PublishedPLoS ONE 7(6): e39646eng
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/1956/6488
dc.description.abstractNGAL/lipocalin-2 is a siderophore-binding protein that is highly expressed in several cancers. It is suggested to confer a proliferative advantage to cancer cells. Its expression has been correlated with aggressiveness of breast cancer as determined both in patients and in mouse breast cancer models. This was recently confirmed in two mouse models of spontaneous breast cancer in wild-type and lipocalin-2-deficient mice. We used a similar strategy using a different mouse strain. Lipocalin-2-deficient mice and mouse mammary tumor virus-polyoma middle T antigen (MMTV-PyMT) mice were crossed into the same FVB/N background. All mice developed tumors by week 8. The mice were sacrificed on week 13 and tissue was processed for biochemical and histological analysis. The total tumor volume and number of metastases were quantitated in 26 lipocalin-2-deficient mice and 34 wild-type controls. Lipocalin-2 expression in tumors of MMTV-PyMT-positive and wild-type mice was assessed by quantitative real-time PCR and by immunohistochemistry. The expression of the lipocalin-2 receptors 24p3R and megalin and of Mmp-9, transferrin receptor, and Bdh2 (a producer of a mammalian siderophore) were quantitated by real-time PCR. No significant difference was observed between wild-type and lipocalin-2-deficient mice. Lipocalin-2 was highly expressed in tumors from wild-type mice, but the expression did not correlate with tumor size. No effect of lipocalin-2 was observed with respect to time to tumor appearance, total tumor volume, or to the number of metastases. Histology and gelatinolytic activity of the mammary tumors did not differ between wild-type and lipocalin-2-deficient mice. We conclude that NGAL/lipocalin-2 does not invariably affect the aggressiveness of breast cancers as assessed in mouse models, thus questioning the role of lipocalin-2 in cancer development.en_US
dc.language.isoengeng
dc.publisherPublic Library of Scienceeng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/eng
dc.titleNo Effect of NGAL/lipocalin-2 on Aggressiveness of Cancer in the MMTV-PyMT/FVB/N Mouse Model for Breast Canceren_US
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2012 Cramer et al.
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0039646
dc.identifier.cristin962007


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY